Prendergast M, Jones J S, Hartman D
Emergency Medicine Residency Program, Butterworth Hospital, Grand Rapids, MI.
Am J Emerg Med. 1994 Nov;12(6):613-6. doi: 10.1016/0735-6757(94)90024-8.
The purpose of this study was to identify a cohort of children with laryngotracheitis (croup) who may be safely discharged from the emergency department (ED) after treatment with nebulized racemic epinephrine (RE), corticosteroids, and prolonged observation. Consecutive children (younger than 13 years of age) presenting to the ED with the diagnosis of laryngotracheitis were evaluated prospectively according to a croup scoring system. Sixty-one patients (4 to 108 months of age) with persistent inspiratory stridor at rest after 20 minutes of mist therapy who received nebulized RE (0.05) mL/kg of a 2.25% solution) and intramuscular dexamethasone (0.6 mg/kg) were enrolled in the study. Patients were observed in the ED while croup scores were assessed at 15, 60, 120, and 180 minutes. Croup scores were significantly improved (analysis of variance, P < .01) throughout the observation period in 31 patients (51%) who were discharged from the ED. Only one patient returned within 48 hours for further cool mist therapy. The maximum benefit from RE therapy was seen at 60 minutes. If a child had persistent resting stridor or a croup score greater than 2 at that time, hospitalization was inevitable. The 30 patients admitted to the hospital were younger (19.1 v 27.8 months) and had higher pretreatment croup scores (5.7 v 4.1). This was the first prospective study to identify a subset of children who have received RE to be safely discharged home after observation in the ED.
本研究的目的是确定一组患有喉气管炎(哮吼)的儿童,他们在接受雾化消旋肾上腺素(RE)、皮质类固醇治疗并延长观察时间后,可以安全地从急诊科(ED)出院。对连续到急诊科就诊且诊断为喉气管炎的13岁以下儿童,根据哮吼评分系统进行前瞻性评估。61例年龄在4至108个月之间、在雾化治疗20分钟后仍有持续性静息吸气性喘鸣的患者纳入研究,这些患者接受了雾化RE(0.05 mL/kg的2.25%溶液)和肌肉注射地塞米松(0.6 mg/kg)治疗。在急诊科观察患者,同时在15、60、120和180分钟时评估哮吼评分。31例(51%)从急诊科出院的患者在整个观察期内哮吼评分显著改善(方差分析,P <.01)。只有1例患者在48小时内返回接受进一步的冷雾化治疗。RE治疗在60分钟时效果最佳。如果此时儿童仍有持续性静息喘鸣或哮吼评分大于2,则不可避免需要住院治疗。30例住院患者年龄更小(19.1个月对27.8个月),治疗前哮吼评分更高(5.7对4.1)。这是第一项前瞻性研究,确定了一组接受RE治疗后在急诊科观察后可安全出院回家的儿童亚组。